One-Time Gene Therapy to be Evaluated in Patients with Early Huntington’s Disease Initiation of VYTAL Phase 1/2 Clinical Trial at Multiple Sites Expected this Year CAMBRIDGE, Mass., April 26, 2021 ...
CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback